Study to Test Safety and Effectiveness of Diosmin and Hesperidin with Standard Treatment for Helicobacter Pylori Infection in Adults 18 to 75 Years

What this Trial Is About

Researchers are studying the possible effectiveness and safety of combining Diosmin and Hesperidin in treating patients with Helicobacter pylori infection. The study focuses on evaluating how this combination affects the eradication of the infection as well as its impact on inflammatory markers such as TNF-A and MDA. This is a randomized, double-blind trial involving adult patients aged 18 to 75 years who have confirmed H. pylori infection. Participants are randomly assigned to one of two groups. One group receives the standard triple therapy consisting of Omeprazole, Clarithromycin, and Amoxicillin along with placebo tablets twice daily for 14 days. The other group receives the same standard triple therapy plus DiosminHesperidin Daflon tablets twice daily for 14 days. Both treatments are administered orally. During the trial, patients are assessed at the start and six weeks after beginning therapy to measure the eradication rate of H. pylori infection using stool antigen tests. Researchers also measure levels of inflammatory biomarkers to observe any changes. Safety and response to treatment are monitored throughout the study, which lasts at least six weeks from therapy initiation.

Clinical Study to Evaluate the Possible Efficacy and Safety of Diosmin and Hesperidin Combined Therapy in Patients With Helicobacter Pylori Infection